Printer Friendly

DURA PHARMACEUTICALS ANNOUNCES AGREEMENT TO CO-MARKET ANTI-ALLERGY PRODUCT

 SAN DIEGO, June 2 /PRNewswire/ -- Dura Pharmaceuticals, Inc. (NASDAQ: DURA) announced today the signing of an agreement with Bausch & Lomb Pharmaceuticals to co-market in North America Pentyde(R) Ophthalmic Solution, Dura's patented, prescription anti- allergy drug, currently being developed for treatment of symptoms associated with allergic conjunctivitis. An earlier agreement between the two companies called for Bausch & Lomb alone to market the product in North America.
 Dura recently completed and is now evaluating the results of a clinical trial and performing additional analyses of previous clinical trials. Both were requested by FDA in support of the NDA (new drug application) filed by Dura in 1990 for marketing approval of Pentyde Ophthalmic Solution.
 "Under this new agreement, both Dura and Bausch & Lomb will promote Pentyde Ophthalmic Solution to our respective target physicians in the U.S.," said Cam L. Garner, Dura Pharmaceuticals president and chief executive officer. "Dura will focus on allergists and other respiratory physicians who have historically prescribed a significant portion of medications use to treat ocular allergy, while Bausch & Lomb will promote the product to eye care professionals. If FDA approves the product for marketing, and there is no assurance it will, this co-promotion arrangement should generate higher total sales of the product than the previous agreement. But equally important," Garner added, "the ability to market Pentyde Ophthalmic Solution would broaden Dura's product line offering, and enhance our positioning with allergists. This would support our overall product sales by increasing our penetration of the allergy market."
 Dura Pharmaceuticals is a San Diego-based developer and marketer of prescription pharmaceutical products, drug delivery systems and medical devices for the treatment of allergies, asthma and related respiratory conditions.
 -0- 6/2/93
 /CONTACT: Cam L. Garner, president and CEO of Dura Pharmaceuticals, 619-457-2553/
 (DURA)


CO: Dura Pharmaceuticals Inc.; Bausch & Lomb Pharmaceuticals ST: California IN: MTC SU: JVN

BP-JB -- SD003 -- 4226 06/02/93 06:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1993
Words:315
Previous Article:SHAW INDUSTRIES IS NAMED IN LAWSUIT
Next Article:DEJA INC. GETS SECOND ROUND OF $1.2 MILLION IN VENTURE CAPITAL; SPRING SELL-THROUGH OF DEJA SHOES PLEASES COMPANY, INVESTORS
Topics:


Related Articles
DURA PHARMACEUTICALS AND ELAN CORPORATION ANNOUNCE SIGNING OF DEFINITIVE STOCK PURCHASE AGREEMENT
DURA PHARMACEUTICALS INC. AND DURA DELIVERY SYSTEMS INC. ANNOUNCE A LICENSE AND SUPPLY AGREEMENT WITH MITSUBISHI CHEMICAL CORP.
DURA PHARMACEUTICALS INC. AND DURA DELIVERY SYSTEMS INC. BEGIN CLINICAL TRIAL OF THE DRYHALER(TM) FOR USE WITH ALBUTEROL
DURA PHARMACEUTICALS SIGNS AGREEMENT WITH BAUSCH & LOMB PHARMACEUTICALS TO CO-PROMOTE OPHTHALMIC ALLERGY DRUG
FUJISAWA TO UTILIZE DURA'S DRY POWDER DRUG DELIVERY SYSTEM IN DEVELOPMENT OF A NEW RESPIRATORY COMPOUND
PHARMOS ANNOUNCES DEFINITIVE MARKETING AGREEMENT WITH BAUSCH & LOMB PHARMACEUTICALS
DURA PHARMACEUTICALS, INC. SIGNS COLLABORATIVE AGREEMENT WITH HOUGHTEN PHARMACEUTICALS, INC.
DURA PHARMACEUTICALS SIGNS AGREEMENT TO CO-PROMOTE A NEW RESPIRATORY DRUG WITH KEY PHARMACEUTICALS
Dura Pharmaceuticals Announces Acquisition of Ceclor(R) CD and Keftab(R) From Eli Lilly
Dura Pharmaceuticals Signs Two Separate Agreements With Major Biotech And Pharmaceutical Companies for Development of Proteins In the Spiros(TM)...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters